

The why

A convergence of factors:

- Patient centric sampling
- Personalized measurement
- Cost burden of healthcare and move to decentralisation
- Drive to population and longitudinal studies leading to big data
- Transition of more sensitive and selective analytical techniques into clinical pathology

This means that **microsampling must evolve** – it is the foundation...

Intervention



- Personal choice
- Clinician driven change

Diagnose



- Interpretation of the results and what do they mean
- Big data based on GOOD data

Test



- Qualified laboratory services
- Workflow integration

Microsampling



- Sample integrity
- Ease of use
- Accessible and affordable

The how

Our mission is to provide **easy-to-use** tools that enable the **remote** and **minimally invasive** collection of biological samples, that are **affordable** and preserve **sample integrity**, whilst being simply **integrated** in to current laboratory workflows.

It's about enabling samples to be taken that would or could not otherwise be taken, to drive information rich decision making.

The hemaPEN® and the microbiopsy device are in development and are for investigational use only.

The what

We started with blood...


hemaPEN® blood sampling device.



...and skin



Microbiopsy device.



The hemaPEN® and the microbiopsy device are in development and are for investigational use only.